Followed by "Introduction to the Academicians of the Department of Medicine and Health of the Chinese Academy of Engineering (VI)" (in alphabetical order of the surname).
Wang Chen, born in August 1962 in Dezhou City, Shandong Province, is an expert in respiratory medicine and critical care medicine, an academician of the Chinese Academy of Engineering, a foreign academician of the National Academy of Medicine, a member of the Faculty of the Chinese Academy of Medical Sciences, a member of the Party Leadership Group and Vice President of the Chinese Academy of Engineering, the president of the Chinese Academy of Medical Sciences (Peking Union Medical College), a member of the Standing Committee of the 14th National Committee of the Chinese People's Political Consultative Conference, the director of the National Clinical Research Center for Respiratory Diseases, and a member of the National Health Science Popularization Expert Database. Vice Chairman of the National Steering Committee for Graduate Education in Medical Specialties.
In 1985, Wang Chen graduated from the Medical Department of Capital Medical University with a bachelor's degree in medicine. In 1991, he received his MD degree from Capital Medical University. In 1994, he was engaged in postdoctoral research at the University of Texas School of Medicine. Since 1993, he has successively served as Deputy Director, Vice President and President of the Department of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Deputy Director of Beijing Institute of Respiratory Diseases, Vice President and Director of Respiratory Center of Beijing Hospital of the Ministry of Health. In February 2013, he was appointed as the deputy director of the Department of Science, Technology and Education of the former Ministry of Health and the National Health and Family Planning Commission. In the same year, he was elected as an academician of the Chinese Academy of Engineering; From September 2014 to January 2018, he served as the President of China-Japan Friendship Hospital. June 2018, Vice President of the Chinese Academy of Engineering.
Wang Chen has long been engaged in medical treatment, teaching and research in the field of respiratory medicine.
Wang Guangji, born on April 26, 1953 in Yangzhou, Jiangsu, is an expert in pharmacokinetics, an academician of the Chinese Academy of Engineering, and a professor and doctoral supervisor of China Pharmaceutical University.
After graduating from China Pharmaceutical University in 1977, Wang Guangji stayed on to work; In 1993, he received his Ph.D. from the University of Otago, New Zealand, and stayed on to engage in postdoctoral research. From 1995 to 2013, he served as Vice President of China Pharmaceutical University. In 2013, he was elected as an academician of the Chinese Academy of Engineering; In 2019, he was appointed as a member of the Faculty of the Chinese Academy of Medical Sciences.
Guangji Wang has been committed to the research and teaching of pharmacokinetics of new drugs.
Wang Hongyang, female, from Weihai, Shandong, academician of the Chinese Academy of Engineering, academician of the Academy of Sciences for Developing Countries, major general, professor, chief physician, doctoral supervisor, expert in medicine and tumor molecular biology. Founding Director of the National Liver Cancer Science Center, Director of the Clinical Medical Center for Oncology of Shanghai Oriental Hepatobiliary Surgery Hospital, and Director of the International Cooperative Biological Signal Transduction Research Center. She is also the chairman of the Chinese Women Scientists Association and the chairman of the Clinical Precision Medicine Professional Committee of the Chinese Medical Doctor Association. He used to be the director of the Medical Department of the National Natural Science Commission, the deputy chief engineer of the National Major Special Project for Infectious Diseases, the vice chairman of the Chinese Anti-Cancer Association, and the deputy editor-in-chief of NPJ Precision Oncology.
Wang Hongyang graduated from the Department of Clinical Medicine of the Second Military Medical University and stayed on as a gastroenterologist in Shanghai Changzheng Hospital. In 1984, he obtained a master's degree in digestive immunology from the Second Military Medical University. In 1989, he studied abroad and received his M.D. degree from the Faculty of Medicine of the University of Ulm, Germany, and worked as a postdoctoral fellow and PI at the Max Planck Institute of Biochemistry of the German Academy of Sciences. In 1997, he returned to Shanghai to found the Sino-German International Research Center for Biosignal Transduction, and served as the executive deputy director of the Shanghai Oriental Institute of Hepatobiliary Surgery. In 2000, he served as the founding director of the Department of Internal Medicine of the Oriental Hepatobiliary Surgery Hospital, and was elected as an academician of the Chinese Academy of Engineering in 2005. The first liver cancer biobank has been built, and an innovation base and talent training base that closely combine cutting-edge basic research and clinical diagnosis and treatment have been built in the hospital. He won the first prize of the National Science and Technology Progress Award, the second prize of the National Natural Science Award, the first prize of the Military Science and Technology Progress Award, the first prize of the Shanghai Natural Science Award and the first prize of the China Anti-Cancer Association. She has won the National Innovation Competition Award (Medal), Wu Jieping Medical Award and National Women's Innovation Model.
Wang Hongyang has been engaged in basic, clinical and translational application research of malignant tumors for a long time, focusing on solving the bottleneck problem of early diagnosis and fine treatment of hepatobiliary tumors in China, and has made important contributions to improving the level of cancer diagnosis and treatment.
Wang Jun, born on November 15, 1963 in Huaibin County, Xinyang City, Henan Province, is an expert in thoracic surgery, an academician of the Chinese Academy of Engineering, the president of Peking University People's Hospital, the director of thoracic surgery, a professor, a doctoral supervisor, the chairman of the Association for Science and Technology, the director of the Thoracic Surgery and Thoracic Minimally Invasive Center, and the director of the thoracic surgery department of Beijing Haidian Hospital.
Wang Jun graduated from Henan Medical University in 1985; In 1989, he received a master's degree in surgery from Beijing Medical University. In 2000, he was appointed as a professor at Peking University. In 2001, he obtained the qualification of doctoral supervisor from Peking University. In 2018, he won the 12th Guanghua Engineering Science and Technology Award; In 2002, he served as the director, professor and chief physician of the Department of Thoracic Surgery, Peking University People's Hospital. In 2017, he served as the dean of the Thoracoscopist Training College of the Chinese Medical Doctor Association; In 2019, he was elected as an academician of the Chinese Academy of Engineering; In 2020, he was appointed as a member of the Faculty of the Chinese Academy of Medical Sciences.
Jun Wang has been working in the clinical frontline, engaged in research on minimally invasive thoracic surgery and lung cancer**.
Wang Junzhi, born on September 30, 1955 in Lanzhou, Gansu Province, is an expert in biological products and biopharmaceutics, an academician of the Chinese Academy of Engineering, the chairman of the Academic Committee of the China Institute for Food and Drug Control, and the chief expert of biological products verification.
Wang Junzhi received a master's degree in pharmacology from Lanzhou Medical College in 1985. In 1993, he received his Ph.D. in molecular pharmacology from the Faculty of Medicine, Mie University, Japan. From 1993 to 1995, he was a postdoctoral researcher at the Faculty of Medicine, Mie University, Japan. From 2001 to 2010, he served as the deputy director of the China Institute for the Control of Pharmaceutical and Biological Products; From 2010 to 2015, he served as the vice president of the China Institute for Food and Drug Control; In 2016, he was appointed as a researcher at the China Institute for Food and Drug Control; In 2019, he was elected as an academician of the Chinese Academy of Engineering;
Wang Junzhi is mainly engaged in the inspection and testing of pharmaceutical and biological products, scientific research management, and research on key technologies for biological drug quality evaluation.
Wang Rui, born on May 25, 1963 in Lanzhou City, Gansu Province, is an expert in medicinal chemistry and peptide drugs, an academician of the Chinese Academy of Engineering, a professor, doctoral supervisor and vice president of Lanzhou University, and the executive director of the Institute of Materia Medica, Chinese Academy of Medical Sciences.
Wang Rui was admitted to Lanzhou University in 1978 and obtained bachelor's, master's and doctoral degrees. After graduating with a master's degree in 1985, he stayed on to teach at Lanzhou University and served as a teaching assistant and lecturer at Lanzhou University. In 1995, he served as a professor and doctoral supervisor of Lanzhou University. From 1997 to 2006, he served as the dean of the School of Life Sciences, Lanzhou University. In 2005, he was awarded the National Science Grant for Distinguished Young Scholars; From 2006 to 2008, he served as the deputy dean of the Graduate School of Lanzhou University. In 2008, he served as the dean of the School of Basic Medical Sciences of Lanzhou University. In 2011, he served as the leader of the "peptide drug" innovation team of the Ministry of Education; In 2016, he was selected as a leading talent of the national "Ten Thousand Talents Program"; In 2017, he was elected as an academician of the Chinese Academy of Engineering; In 2018, he served as the vice president of Lanzhou University; In 2019, he was appointed as a member of the Faculty of the Chinese Academy of Medical Sciences. In 2021, he was appointed as the Executive Director of the Institute of Materia Medica, Chinese Academy of Medical Sciences.
Rui Wang's research focuses on peptide medicinal chemistry and peptide drugs and chiral drugs, as well as peptides and proteins, biochemistry and the molecular basis of diseases.
Wu Tangchun, born on July 25, 1965 in Jianyang, Sichuan, is an occupational health and environmental health scientist, academician of the Chinese Academy of Engineering, dean of Tongji Medical College of Huazhong University of Science and Technology, dean of the School of Public Health, professor, doctoral supervisor, and vice chairman of Hubei Science and Technology Association
Wu Tangchun graduated from Tongji Medical University in 1988 with a major in preventive medicine. In 1993, he received his M.D. degree from Tongji Medical University. From 1995 to 1996, he was a postdoctoral researcher at the Laboratory of Molecular Genetics and Development, Laval University, Canada. In 2000, he was hired as a doctoral supervisor; In 2001, he served as the deputy dean of the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology. In 2003, he also served as the director of the Pesticide Toxicology Research Center of Tongji Medical College of Huazhong University of Science and Technology; In 2005, he was awarded the National Science Grant for Distinguished Young Scholars; In 2006, he served as the dean of the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology. In 2009, he was selected as a national candidate for the "New Century Millions of Talents Project"; In 2021, he was elected as an academician of the Chinese Academy of Engineering.
Wu Tangchun has long been engaged in research on air pollution and health.
Wu Yiling, born on October 24, 1949 in Gucheng County, Hengshui City, Hebei Province, is an expert in cardiovascular diseases of traditional Chinese medicine, an academician of the Chinese Academy of Engineering, an academic vice president, professor and doctoral supervisor of Hebei Medical University, a lifelong honorary president of Hebei University of Traditional Chinese Medicine, and a lifelong honorary chairman of Yiling Pharmaceutical Industry.
Wu Yiling followed his father to practice medicine since he was a child. In 1977, Wu Yiling entered the Department of Traditional Chinese Medicine of Hebei Medical University to study for a bachelor's degree. In September 1979, Wu Yiling entered Nanjing University of Chinese Medicine to study for a master's degree in the clinical foundation of traditional Chinese medicine. In 1982, he graduated from the first master's degree of Nanjing College of Traditional Chinese Medicine and was assigned to work in the Department of Cardiovascular Medicine of Hebei Provincial Hospital of Traditional Chinese Medicine. In 1992, the Medical Research Institute of Shijiazhuang Development Zone was officially opened; In 2006, Beijing Yiling Pharmaceutical Co., Ltd. was registered and established, and in 2009, he was elected as an academician of the Chinese Academy of Engineering; In 2012, he was rated as the first batch of leading talents of innovation and entrepreneurship teams in Hebei Province's "Giant Plan"; In 2019, he was elected as a member of the Faculty of the China Academy of Chinese Medical Sciences, and won the first prize of the National Science and Technology Progress Award for "The Construction of Context Theory and Its Guidance for the Prevention and Treatment of Microvascular Lesions".
Wu Yiling has been engaged in the research of the theory of traditional Chinese medicine network disease, and is good at the theory of traditional Chinese medicine network disease and the diagnosis and treatment of various cardiovascular and cerebrovascular diseases such as coronary heart disease, arrhythmia, chronic heart failure, and stroke. Wu Yiling has won 1 second prize of the National Science and Technology Invention Award, 3 second prizes of the National Science and Technology Progress Award, 5 first prizes of the provincial and ministerial level and the Ho Leung Ho Li Award. Wu Yiling's monograph "Network Disease" won the first prize of academic works of the Chinese Association of Traditional Chinese Medicine, and published more than 6,000 research articles and more than 300 SCI articles in China.
To be continued) List of high-quality authors